Company Profile
Genome & Company, a clinical stage biotechnology company researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism globally.
Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. It also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products
Including therapeutics, cosmeceuticals, and dietary supplements. Additionally, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD) Disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). Founded in 2015, the company is headquartered in Suwon-si, South Korea.